On July 28, Novo-Nordisk A/S rose 3.01% in regular trading, trading at $51.06/share, with turnover of $194 million.

On the news front, Novo Nordisk filed a preliminary injunction motion with the US District Court for the District of New Jersey, requesting an immediate halt to Eli Lilly's advertising campaigns for its obesity drug Zepbound and diabetes drug Mounjaro during the ongoing litigation.

The motion escalates a legal dispute that began earlier when Novo Nordisk formally sued Lilly, alleging its ads violated federal and state false advertising and unfair competition laws. Specifically, Novo claims Lilly's campaigns compare Zepbound and Mounjaro with lower doses of Wegovy and Ozempic while omitting information about higher-dose semaglutide formulations, rendering the ads misleading. Lilly denied the allegations and stated it will vigorously defend the lawsuit.

The legal battle reflects intensifying competition in the GLP-1 weight-loss drug market, where Lilly currently commands approximately 60% market share versus Novo Nordisk's 40%. Novo Nordisk is also pursuing broader cost-reduction measures, including supplier price negotiations and workforce restructuring, to improve its competitive positioning.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)